Evaluating the effects of certain drugs on liver fibrosis
Clinical Study Evaluating the Efficacy of Renin Angiotensin System Inhibitors on the Extent of Liver Fibrosis in Patients With Chronic Hepatitis C
This study is testing whether the medications Candesartan and Ramipril can help improve liver health in people with liver fibrosis caused by chronic hepatitis C.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 45 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Tanta) |
| Trial ID | NCT03770936 on ClinicalTrials.gov |
What this trial studies
This study evaluates the impact of two medications, Candesartan and Ramipril, on patients suffering from liver fibrosis due to chronic hepatitis C. It is designed as a Phase 3 interventional trial, focusing on assessing the efficacy of these drugs in improving liver health. The study aims to gather comprehensive data on how these treatments can influence the progression of liver fibrosis.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with chronic hepatitis C who are experiencing liver fibrosis.
Not a fit: Patients with acute hepatitis or thalassemia may not receive any benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide new therapeutic options for patients with liver fibrosis, potentially improving their liver function and overall health.
How similar studies have performed: There is limited information on the success of similar studies, making this approach somewhat novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * chronic hepatitis C Exclusion Criteria: * Acute hepatitis * Thalassemia
Where this trial is running
Tanta
- Sherief Abd-Elsalam — Tanta, Egypt (Recruiting)
Study contacts
- Principal investigator: Gamal El-azab, Prof — Clinical pharmacy Department- Tanta University
- Study coordinator: Sherief Abd-Elsalam, Ph D
- Email: sheriefabdelsalam@yahoo.com
- Phone: 00201147773440
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.